NeuroVive, Sihuan deal

NeuroVive's NeuroVive Pharmaceutical Asia Ltd. subsidiary granted Sihuan's Sun Moral International Ltd. subsidiary rights to develop and commercialize NeuroVive's CicloMulsion and NeuroSTAT in China. NeuroVive is eligible for up to RMB35 million ($5.6 million) for CicloMulsion and up to RMB12 million ($1.9 million) for NeuroSTAT in upfront and milestone payments. NeuroVive is also eligible for 10% royalties for the 10 years following the launch of the products.

NeuroVive is evaluating CicloMulsion in the European Phase III CIRCUS trial to treat reperfusion injury following myocardial infarction (MI). Sihuan plans to start a Chinese Phase II/III trial of the cremophor-free IV cyclosporine formulation for the indication next year. ...